DIRS.INFO The most relevant business & tech news

LONDON, April 27 (Reuters) - AstraZeneca (AZN.L) on Thursday beat expectations for its first -quarter profit and revenue, helped by sales of its roster of drugs in emerging markets. The London-listed drugmaker, which reports its results in U.S. dollars, reported adjusted profit of $1.92 per share on sales of about $10.9 billion. Excluding sales of its COVID-19 products, sales grew 22% to $3.1 billion in emerging markets on a constant currency basis. AstraZeneca's best-selling cancer drugs — Tagrisso, Imfinzi and Lynparza — generated $1.4 billion, $900 million and $651 million of sales, respectively, in the quarter. Cowen analysts expected the three drugs to bring in about $1.45 billion, $735 million and $700 million respectively, in quarterly sales.

LONDON, April 26 (Reuters) - GSK (GSK.L) began 2023 with a quarterly performance that beat analyst expectations and extended a series of positive results following strong sales of its roster of vaccines as well as HIV and respiratory medicines. Investors are also concerned about the company's long-term prospects, given the pending loss of patent protection of one of GSK's HIV compounds and setbacks in its marketed oncology portfolio. GSK is also relying in part on its potential blockbuster vaccine for RSV, which leads to thousands of hospitalisations and deaths each year. It anticipates launching the vaccine later this year in the U.S. and Europe, pending regulatory approval, as does rival Pfizer (PFE.N). ($1 = 0.8039 pounds)Reporting by Maggie Fick and Natalie Grover in London, Editing by Louise HeavensOur Standards: The Thomson Reuters Trust Principles.

LONDON, March 2 (Reuters) - Haleon (HLN.L), the world's biggest standalone consumer health business with brands such as Sensodyne toothpaste and Advil painkillers, reported its first full-year results on Thursday which analysts said were in line with expectations. Analysts said on Thursday that Haleon has had a strong start to 2023, and its full-year revenue growth forecast of 4% to 6% was in line or just ahead of consensus estimates. Rivals with consumer health operations, such as Bayer (BAYGn.DE) and Reckitt (RKT.L), have charged higher prices to partly offset broader falls in sales volumes. "Our organic (full-year) revenue growth ... was well balanced between volume and price, with two thirds of the business gaining or holding share," McNamara said. Haleon, which is made up of assets previously owned by GSK and Pfizer (PFE.N) reported organic revenue growth of 9% last year, just ahead of the 8-8.5% increase it predicted for 2022.

The company also predicted a return to growth in China, one of its key markets, after reporting a second consecutive quarter of growth even as prices remain under pressure. Sales of its best-selling cancer drugs — Tagrisso, Imfinzi and Lynparza — came in just below estimates from Cowen analysts. Sales started to pick up in the second half of 2022 and in the fourth quarter grew by 3% at constant currency rates. Of key interest to investors is the experimental cancer drug, datopotamab deruxtecan, being evaluated in a keenly anticipated late-stage trial involving lung cancer patients. Partner Daiichi Sankyo (4568.T) this month said results of that study have been delayed to the second quarter from the first quarter of 2023.

[1/2] The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/Companies AstraZeneca PLC FollowLONDON, Feb 9 (Reuters) - Britain's business climate is deterring biopharma companies from investing in the country, AstraZeneca (AZN.L) chief Pascal Soriot said on Thursday, highlighting his company's decision to shift plans for a new manufacturing plant to Ireland. He highlighted AstraZeneca's recent decision to build a manufacturing facility in Ireland instead of the UK as evidence of Britain becoming less attractive for drugmakers. The decision, made in 2021, was also linked to the UK government's Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a company spokesperson added. Reporting by Natalie Grover and Maggie Fick Editing by Tomasz Janowski, Barbara Lewis and Susan FentonOur Standards: The Thomson Reuters Trust Principles.

LONDON, Feb 1 (Reuters) - GSK (GSK.L) chief executive Emma Walmsley on Wednesday made replenishing the drugmaker's pipeline of vaccines and therapies her number-one priority. But analysts say there is not enough in the medicine cabinet to keep the momentum going even beyond the next few years. Meanwhile, analysts say the market for Shingrix will eventually become saturated, further limiting the company's growth prospects. GSK shares lagR&D SPENDGSK's spending on R&D has long lagged behind its peers, something activist investor Elliott highlighted in a 2021 letter pressuring the company to make sweeping changes. Lucy Coutts, investment director at wealth management firm JM Finn, which holds GSK shares, there is hope the company will eventually deliver a streamlined and specialist portfolio of blockbuster drugs.

The main active ingredient in Ozempic is semaglutide, which is also the key ingredient in Novo's obesity drug Wegovy. Several less efficacious obesity drugs from multiple drugmakers have previously been approved, but bungled launches and serious side effects led to tepid sales and even some market withdrawals. Novo faces looming competition from Eli Lilly (LLY.N), whose weekly injection Mounjaro won U.S. approval for type 2 diabetes in May and is under fast-track review as a weight-loss drug. Amgen (AMGN.O) also has an early-stage, once-monthly obesity drug that is being keenly watched. Elon Musk, the world's richest person and now Twitter owner, has offered his own endorsement of the weight-loss benefits of semaglutide on the social media website.

Search resuls for: "Natalie Grover Maggie Fick"

7 mentions found